Ergot-derived dopamine agonist
Cabergoline
Cabergoline is an ergot-derived dopamine receptor agonist; the app lists a half-life of 63 hours, and the US label gives 63 to 69 hours from urinary data in 12 healthy subjects.1
Cabergoline after one dose: 50% at ~63 h, 25% at 126 h, 12.5% at 189 h.
Drawn from the half-life in the app's model, ~63 h. The model's figures
- Compound
- Cabergoline
- Symbol
- CAB
- Family
- Post-cycle and ancillaries
- Parts
- 14
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Cabergoline is an ergot derivative and dopamine receptor agonist with a high affinity for D2 receptors, according to its US prescribing information.1 The US label gives its indication as hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas, in adults, and states that cabergoline tablets are not approved for Parkinson's disease.1
The UK summary of product characteristics for Dostinex (Pfizer Limited) also lists inhibition and suppression of physiological lactation after delivery, while the US label lists a limitation of use for postpartum lactation inhibition or suppression because of the risk of serious adverse reactions.2,1 The app lists a half-life of 63 hours, a bioavailability of 95%, a time to peak of 3 hours and a typical dose of 0.25 to 0.5 mg a day, and the sources below give their own figures beside each of them.1,2
How it works
In cells and animals
The US label reports in vitro studies in which cabergoline had a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs, and a decrease in serum prolactin levels in reserpinized rats.1 The UK summary states that cabergoline acts by direct stimulation of D2-dopamine receptors on pituitary lactotrophs, thus inhibiting prolactin secretion.2
In people
The UK summary states that after a single oral dose of 0.3 to 1.5 mg a significant decrease in serum prolactin was observed in healthy volunteers, puerperal women and hyperprolactinaemic patients, and that the effect is "prompt (within 3 hours from administration)".2 Andreotti and colleagues (Journal of Clinical Endocrinology and Metabolism, 1995) gave single oral doses of 0.5, 1.0 and 1.5 mg to 12 healthy men and reported complete prolactin suppression (below 1.0 micrograms/L) in every subject who received each dose, occurring earlier and persisting longer with the two higher doses.3
Receptor activity and fibrosis
A 2008 review of dopamine agonists in Parkinson's disease and restless legs syndrome (Kvernmo and colleagues, Current Topics in Medicinal Chemistry) states that valvular heart disease and pulmonary and retroperitoneal fibrosis "appear to represent a class effect of 8beta-aminoergolines as cabergoline and pergolide".4
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~63 h
- Bioavailability
- 95%
- Typical dose
- 0.25–0.5 mg/day
- Route
- Oral
- Time to peak
- ~3 h
Sources in this part
The US label gives an elimination half-life of cabergoline, estimated from urinary data of 12 healthy subjects, of 63 to 69 hours.1 The UK summary gives 63 to 68 hours in healthy volunteers (radio-immuno assay) and 79 to 115 hours in hyperprolactinaemic patients (HPLC method).2 The app's figure of 63 hours equals the lower end of the US label's range and is below the UK summary's range for hyperprolactinaemic patients.1,2
The chart below draws the app's half-life of 63 hours and time to peak of 3 hours as a one-compartment model; the twice-weekly interval is the one the US label states and the once-weekly interval is one the UK summary describes.1,2
| Parameter | Value | Note |
|---|---|---|
| Half-life | ~63 hours (the app's figure) | US label: 63 to 69 hours (urinary data, 12 healthy subjects). UK summary: 63-68 hours in healthy volunteers (radio-immuno assay) and 79-115 hours in hyperprolactinaemic patients (HPLC method).1,2 |
| Bioavailability (oral) | ~95% (the app's figure) | US label: the absolute bioavailability of cabergoline is unknown, and a significant fraction of the administered dose undergoes a first-pass effect.1 |
| Time to peak | ~3 hours (the app's figure) | US label: 2 to 3 hours after single oral doses of 0.5 mg to 1.5 mg in healthy subjects. Andreotti and colleagues: median 2 hours at all three doses in 12 healthy men. UK summary: peak of radioactivity in plasma between 0.5 and 4 hours.1,3,2 |
| Duration of activity | ~7 days (the app's figure, 168 hours) | UK summary: after a single oral dose of 0.3 to 1.5 mg the prolactin-lowering effect persisted up to 7 - 28 days in healthy volunteers and hyperprolactinaemic patients, and up to 14 - 21 days in puerperal women.2 |
Andreotti and colleagues concluded that in the 0.5 to 1.5 mg range the pharmacokinetics of cabergoline are dose independent, and also reported that systolic and diastolic blood pressure fell progressively and that symptomatic hypotension after the 1.0 mg dose meant one subject did not receive the 1.5 mg dose, that other mild to moderate adverse events occurred only after the 1.0 and 1.5 mg doses, and that the frequencies of adverse events were dose related.3 PubMed's record of that study names no sponsor and states no limitations.3
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Webster and colleagues, 19945 | Multicenter randomized trial of cabergoline against bromocriptine; double-blind for 8 weeks, then open for 16 weeks | 459 women with hyperprolactinemic amenorrhea (223 on cabergoline, 236 on bromocriptine) | Cabergoline 0.5 to 1.0 mg twice weekly; bromocriptine 2.5 to 5.0 mg twice daily; 6 months | Stable normoprolactinemia in 186 of 223 (83%) against 138 of 236 (59%), P < 0.001; ovulatory cycles or pregnancy 72% against 52%; amenorrhea persisted in 7% against 16%; adverse effects 68% against 78% (P = 0.03); stopped for drug intolerance 3% against 12%. |
| US label, Study 11 | Randomized, double-blind, placebo-controlled for 4 weeks, then a 12-month open-label extension | 188 non-pregnant hyperprolactinemic females, mean age 32 years (range 16 to 46) | Twice weekly for 4 weeks: placebo (n=20); cabergoline 0.25 then 0.5 mg, 0.375 then 0.75 mg, or 0.5 then 1 mg (n=42 each) | Normal serum prolactin at 4 weeks in 0% on placebo and 76%, 74% and 95% on the three cabergoline dosages (p < 0.0001); a further group (n=42, 0.0625 then 0.125 mg) is not presented because the label states that dosage was not effective. |
| US label, Study 21 | Randomized, double-blind, active-control for 8 weeks, then a 16-week open extension | 459 patients with hyperprolactinemic amenorrhea (223 on cabergoline, 236 on bromocriptine); mean age 31 years | Cabergoline 0.5 mg twice weekly; bromocriptine 2.5 mg twice daily; 8 weeks | At 8 weeks, normal serum prolactin in 77% against 59%, restoration of menses 77% against 70%, disappearance of galactorrhea 73% against 56%; attrition 46% and 43%; no sponsor is named in the label. |
| dos Santos Nunes and colleagues, 20116 | Systematic review and meta-analysis of randomized controlled trials of cabergoline against bromocriptine | Four publications included from 418 references identified (Embase, Pubmed, Lilacs and Cochrane Central) | Doses and lengths not given in the PubMed record | Normalization of prolactin RR 0.67 (95% CI 0.57 to 0.80) and menstruation with return of ovulatory cycle RR 0.74 (0.67 to 0.83), reported as a significant difference in favor of cabergoline (the PubMed record does not state which event the ratios count); adverse effects significantly higher with bromocriptine, RR 1.43 (1.03 to 1.98). |
| Colao and colleagues, 20037 | Observational, prospective study of cabergoline withdrawal | 200 patients: 25 nontumoral hyperprolactinemia, 105 microprolactinomas, 70 macroprolactinomas | Withdrawal once prolactin was normal and MRI criteria were met; follow-up of at least 24 months | Recurrence two to five years after withdrawal 24%, 31% and 36% respectively; renewed tumor growth in no patient; gonadal dysfunction redeveloped in 10 female (22%) and 7 male (39%) patients with recurrent hyperprolactinemia. |
| De Rosa and colleagues, 20048 | Open longitudinal study, with 51 healthy men as controls | 51 consecutive men with hyperprolactinemia (41 macroprolactinomas, 10 microprolactinomas) | 6 months of cabergoline; dose not given in the PubMed record | Prolactin normalized in 74.5% and testosterone in 68.6%; nocturnal penile tumescence normalized in 60.6% of patients whose prolactin normalized and 7.7% of those whose prolactin did not. |
| Budayr and colleagues, 20209 | Cross-sectional study of echocardiograms read blinded to agonist type and duration | 174 adults treated for more than 12 months for hyperprolactinemia, no cardiac symptoms: 62 cabergoline only, 63 bromocriptine only, 49 both | Median cabergoline use 2.8 years (cabergoline only) and 3.2 years (both) | Regurgitation of at least 1 valve in 37.1% on cabergoline only, 26.5% on both and 17.5% on bromocriptine only (P = 0.02 and 0.26 against bromocriptine only); of at least 2 valves 11.3%, 12.2% and 1.6%; primarily mild regurgitation. |
Deeper analysis: Webster and colleagues, New England Journal of Medicine, 1994
Webster and colleagues, in a paper from the Cabergoline Comparative Study Group (first author at the University of Wales College of Medicine, Cardiff), assigned 459 women with hyperprolactinemic amenorrhea to cabergoline or bromocriptine, double-blind for 8 weeks and then open for 16 weeks, with doses adjusted to response during the open phase.5 The authors concluded: "Cabergoline is more effective and better tolerated than bromocriptine in women with hyperprolactinemic amenorrhea", while adverse effects were still recorded in 68% on cabergoline and 78% on bromocriptine.5 PubMed lists the paper under "Research Support, Non-U.S. Gov't" and names no sponsor, and the record carries no statement of the authors' ties to a sponsor or of the authors' limitations.5 The US label's Study 2, with the same group sizes of 223 and 236, reports a normal serum prolactin level at 8 weeks in 77% and 59%, and in its 8-week double-blind period 2% (4 of 221) of cabergoline-treated and 6% (14 of 231) of bromocriptine-treated patients stopped because of an adverse event1, a different denominator and definition from the 3% and 12% who stopped for drug intolerance in the paper.5
Deeper analysis: Schade, Zanettini and colleagues, New England Journal of Medicine, 2007
Schade and colleagues (Charité-Universitätsmedizin Berlin) built a cohort of 11,417 people aged 40 to 80 from the United Kingdom General Practice Research Database who were prescribed antiparkinsonian drugs between 1988 and 2005, and matched each of 31 patients with newly diagnosed cardiac-valve regurgitation to up to 25 control subjects.10 Of the 31 cases, 6 were currently exposed to cabergoline and 19 had not been exposed to any dopamine agonist within the previous year, and the incidence-rate ratio for current cabergoline use was 4.9 (95% CI 1.5 to 15.6), against 7.1 (2.3 to 22.3) for pergolide and no increase for other dopamine agonists.10 Zanettini and colleagues (Istituti Clinici di Perfezionamento, Milan) compared echocardiograms of 155 people taking dopamine agonists for Parkinson's disease with 90 control subjects and reported grade 3 to 4 regurgitation in any valve in 28.6% of 49 on cabergoline, 23.4% of 64 on pergolide, 0% of 42 on non-ergot-derived agonists and 5.6% of controls.11 PubMed names no sponsor, author ties or limitations for either paper and lists Zanettini's under "Research Support, Non-U.S. Gov't".11,10 Both studies were in people taking antiparkinsonian drugs, and the US label states that postmarketing valvulopathy cases have generally occurred at high doses (>2 mg/day) given for Parkinson's disease, with cases also reported at lower dosages for hyperprolactinemic disorders.1
Deeper analysis: Colao and colleagues, New England Journal of Medicine, 2003
Colao and colleagues (Federico II University of Naples) studied 200 patients in whom cabergoline withdrawal was considered once prolactin was normal and MRI showed no tumor, or tumor reduction of 50 percent or more away from the optic chiasm and without invasion of the cavernous sinuses.7 The authors concluded that "Cabergoline can be safely withdrawn in patients with normalized prolactin levels and no evidence of tumor", and also wrote that the length of follow-up "was insufficient to rule out a delayed increase in the size of the tumor", so they suggested close monitoring, particularly of patients with macroprolactinomas.7 The five-year Kaplan-Meier recurrence estimate was higher with small remnant tumors on MRI than with no evidence of tumor, 78% against 33% in macroprolactinomas (P=0.001) and 42% against 26% in microprolactinomas (P=0.02), and PubMed lists the paper under "Research Support, Non-U.S. Gov't" without naming a sponsor.7
Deeper analysis: Budayr and colleagues, BMC Endocrine Disorders, 2020
Budayr and colleagues (Kaiser Permanente Northern California) read transthoracic echocardiograms, blinded to the type and duration of dopamine agonist, in 174 adults who had received cabergoline or bromocriptine for more than 12 months for hyperprolactinemia and had no cardiac-related symptoms.9 Regurgitation of at least 1 valve was more common with cabergoline only than with bromocriptine only (37.1% against 17.5%, P = 0.02) but not with combined exposure (26.5%, P = 0.26), regurgitation of at least 2 valves was more common with cabergoline only (11.3% against 1.6%, P = 0.03) and with combined exposure (12.2%, P = 0.04), and, compared with bromocriptine only, a cumulative cabergoline exposure above 115 mg was associated with an age-sex adjusted odds ratio of 9.6 (95% CI 1.1 to 81.3, P = 0.04) for at least 2 valves with grade 2+ regurgitation, while exposure of 115 mg or less gave an adjusted odds ratio of 7.7 (95% CI 0.9 to 66.6, P = 0.06).9 The authors wrote that "all but one of the cases of valvular regurgitation in this cross-sectional study of asymptomatic adults was mild", that they "cannot rule out residual confounding as an explanation for our findings", that they had no echocardiographic information on patients with hyperprolactinemia who were not treated with dopamine agonist therapy, that they "had limited precision for examining the association of cumulative cabergoline dose and valvular abnormalities", and that the clinical significance of the findings "is less clear in this population".9 The study was supported by the Kaiser Permanente Northern California Community Benefit Fund, and the authors declare that they have no competing interests.9
Doses reported in studies and on labels
| Source | Dose | Frequency | Length |
|---|---|---|---|
| The app's typical dose | 0.25–0.5 mg | A day, as the app writes it | None stated in the app's figure |
| US label, hyperprolactinemic disorders1 | Starting 0.25 mg orally, increased by 0.25 mg at intervals of no less than 4 weeks; maximum 1 mg | Twice weekly | Titrated to normal serum prolactin |
| UK summary, hyperprolactinaemic disorders2 | Initial 0.5 mg per week; usually 1 mg per week, range 0.25 mg to 2 mg per week; up to 4.5 mg per week has been used; the summary also states a maximum of 3 mg per day | One or two doses per week; the weekly dose may also be divided into two or more doses | Increased by 0.5 mg per week, preferably at monthly intervals |
| Andreotti and colleagues, 19953 | Single oral doses of 0.5, 1.0 and 1.5 mg | Single doses | 5-week washout between doses |
Sources in this part
The app's typical dose is written per day, while the rows above for the US label, the UK summary's hyperprolactinaemic dosage and Andreotti and colleagues give weekly, twice-weekly or single-dose schedules, and none of them lists a daily dose of 0.25 to 0.5 mg, although the UK summary states a maximum of 3 mg per day.1,2,3
Side effects reported
Sources in this part
The US label states that the most common adverse reactions (incidence >10%) are nausea, headache, and dizziness.1 In its 4-week placebo-controlled trial (168 on cabergoline, equal to the four groups of 42 that include the dosage the label calls not effective, and 20 on placebo), nausea occurred in 27% against 20%, headache in 26% against 25%, dizziness in 15% against 5% and postural hypotension in 4% against 0%.1 In the 8-week comparison with bromocriptine, nausea occurred in 29% on cabergoline (n=221) against 43% on bromocriptine (n=231), headache in 26% against 27%, dizziness in 17% against 18%, and 2% on cabergoline and 6% on bromocriptine discontinued because of an adverse event.1 The UK summary states that adverse events are generally dose-related and lists valvulopathy (including regurgitation) and related disorders (pericarditis and pericardial effusion) among the very common (at least 1 in 10) effects.2
The US label warns of cardiac valvulopathy and pericardial fibrosis and states that cases of valvular and pericardial fibrosis "have often manifested as heart failure".1 It cites a 12-year, multi-country retrospective cohort study in which cardiac valvular regurgitation incidence per 10,000 person years was 68 (95% CI 37 to 115) with cabergoline for Parkinson's disease, against 10 (95% CI 5 to 19) with non-ergot dopamine agonists and 11 (95% CI 7 to 17) with levodopa.1 It also reports postmarketing pleural, pulmonary and retroperitoneal fibrosis, and lists as contraindications uncontrolled hypertension, hypersensitivity to ergot derivatives, a history of cardiac valvular disorders or pericardial fibrosis, and a history of pleural, pulmonary or retroperitoneal fibrotic disorders.1 The 2019 joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology (Steeds and colleagues, Clinical Endocrinology) states that "Evidence of clinically significant valve pathology is absent, except for isolated case reports around which questions remain".12 The same statement calls evidence that dopamine agonist therapy causes abnormal valve morphology and dysfunction at doses used in the management of hyperprolactinaemia "extremely limited".12 The same statement calls for a standard transthoracic echocardiogram before dopamine agonist therapy for hyperprolactinaemia starts, repeat echocardiography 5 years after starting cabergoline at a total weekly dose of 2 mg or less, and annual echocardiography above 2 mg a week.12 The US label directs an evaluation for valvular heart disease, including an echocardiogram, before starting and echocardiograms at intervals of 6 to 12 months or as clinically indicated afterwards, and the UK summary states that valvulopathy has been associated with cumulative doses.1,2
The US label describes impulse control disorders and compulsive behaviors, with intense urges to gamble or to spend money, increased sexual urges and binge eating, which in some cases were reported to have stopped when the dosage was reduced or the drug was stopped.1 Increased libido is in the US label's list of events reported at an incidence below 1% in clinical studies, and its postmarketing list names hypersexuality, increased libido and pathological gambling, reactions the label says are reported voluntarily from a population of uncertain size.1
Bloodwork and markers
Sources in this part
Serum prolactin is the marker the US label's randomized studies measured: the endpoint of its Study 1 was the percentage of patients who achieved a normal serum prolactin level at the end of the 4-week treatment period.1 In De Rosa and colleagues' 51 men with hyperprolactinemia, testosterone deficiency was present at baseline in 73.2% of those with macroprolactinomas and 50% of those with microprolactinomas, and after 6 months of cabergoline testosterone levels had normalized in 68.6% of patients.8 The UK summary states that, for endocrine effects not related to the antiprolactinaemic effect, available data from humans indicate a very selective action, with no effect on basal secretion of other pituitary hormones or cortisol.2
Regulatory and anti-doping status
The US label for cabergoline tablets (Teva Pharmaceuticals USA, Inc.) shows initial US approval in 1996, and the UK summary of product characteristics for Dostinex is held by Pfizer Limited and was last updated on the electronic medicines compendium on 20 September 2024.1,2 The WADA 2026 Prohibited List, which came into effect on 1 January 2026, does not contain the word cabergoline in its text.13 Several of the list's classes, such as S4.1 and S4.2, are introduced with the words "Including, but not limited to".13
Storage and handling
Sources in this part
What is not known
Sources in this part
The US label states that the absolute bioavailability of cabergoline is unknown, while the app lists 95%.1 It also states that the exposure-response relationship and time course of pharmacodynamic response have not been fully characterized.1 Budayr and colleagues wrote that "even larger additional studies with longer-term exposure of observed daily doses are needed" to confirm their valve findings.9 PubMed searches on 16 November 2026 for "cabergoline nandrolone OR trenbolone prolactin" and for "cabergoline anabolic steroid prolactin gynecomastia" returned seven records and no records respectively; the seven titles name steers, mares, sows, sheep, cull beef cows and anabolic implants, and none describes a study of cabergoline in people given those steroids.
Frequently asked questions
What is the half-life of cabergoline?
What is the time to peak of cabergoline?
What is the bioavailability of cabergoline?
The US label states that the absolute bioavailability of cabergoline is unknown, and the app lists 95%.1
What is cabergoline used for?
Is cabergoline banned by WADA?
The text of the WADA 2026 Prohibited List does not contain the word cabergoline, and classes such as S4.1 and S4.2 are introduced with the words "Including, but not limited to", so the absence of the word does not show whether a substance falls under a class.13
What are the side effects of cabergoline?
Does cabergoline affect heart valves?
The US label warns of cardiac valvulopathy and pericardial fibrosis, and states that cases have generally occurred at doses above 2 mg/day given for Parkinson's disease, with cases also reported at lower dosages for hyperprolactinemic disorders.1 In Budayr and colleagues' study of 174 adults treated for hyperprolactinemia, regurgitation of at least 1 valve was observed in 37.1% on cabergoline only against 17.5% on bromocriptine only (P = 0.02) and 26.5% on both (P = 0.26), all but one of the cases was mild, and the authors wrote that they cannot rule out residual confounding.9
How does cabergoline compare with bromocriptine?
Webster and colleagues reported stable normoprolactinemia in 83% of women on cabergoline and 59% on bromocriptine (P < 0.001) among 459 women with hyperprolactinemic amenorrhea, with adverse effects recorded in 68% and 78%.5 A systematic review of four publications reported a significant difference in favor of cabergoline for normalization of prolactin (RR 0.67, 95% CI 0.57 to 0.80; the PubMed record does not state which event the ratio counts).6
Is there a study of cabergoline with nandrolone or trenbolone?
PubMed searches on 16 November 2026 for "cabergoline nandrolone OR trenbolone prolactin" and for "cabergoline anabolic steroid prolactin gynecomastia" returned seven records and no records respectively; the seven titles name steers, mares, sows, sheep, cull beef cows and anabolic implants, and none describes a study of cabergoline in people given those steroids.
Guides, tools and comparisons
References
- Teva Pharmaceuticals USA, Inc. Cabergoline tablets, prescribing information (US label, Rev. H 6/2025). DailyMed 2025. DailyMed label
- Pfizer Limited. Dostinex 0.5 mg Tablets, Summary of Product Characteristics (UK), electronic medicines compendium, updated 20 September 2024. UK SmPC
- Andreotti AC, et al. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline after increasing oral doses (0.5, 1.0, and 1.5 mg) in healthy male volunteers. J Clin Endocrinol Metab 1995. PMID 7883840
- Kvernmo T, et al. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem 2008. PMID 18691132
- Webster J, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994. PMID 7915824
- dos Santos Nunes V, et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 2011. PMID 21221817
- Colao A, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003. PMID 14627787
- De Rosa M, et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004. PMID 14764772
- Budayr A, et al. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC Endocr Disord 2020. PMC7031983
- Schade R, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007. PMID 17202453
- Zanettini R, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007. PMID 17202454
- Steeds R, et al. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement. Clin Endocrinol 2019. PMID 30818417
- World Anti-Doping Agency. Prohibited List 2026 (in effect 1 January 2026). WADA Prohibited List 2026